LIVIVO - Search results -

Search results

Result 1 - 10 of total 21

Search options

Article ; Online: Crown Macromolecular Derivatives: Stepwise Design of New Types of Polyfunctionalized Phosphorus Dendrimers.

Karpus, Andrii / Mignani, Serge / Zablocka, Maria / Majoral, Jean Pierre

2022 Volume 87, Issue 5, Page(s) 3433–3441

Abstract: Phosphorus dendrimers are used for many applications in different domains including nanomedicine as cargo of drugs or as species ... ...

Abstract	Phosphorus dendrimers are used for many applications in different domains including nanomedicine as cargo of drugs or as species active
MeSH term(s)	Catalysis ; Dendrimers/chemistry ; Nanomedicine ; Phosphorus/chemistry
Chemical Substances	Dendrimers ; Phosphorus (27YLU75U4W)
Language	English
Publishing date	2022-02-10
Publishing country	United States
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	123490-0
ISSN	1520-6904 ; 0022-3263
ISSN (online)	1520-6904
ISSN	0022-3263
DOI	10.1021/acs.joc.1c03009
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 4473: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Bioactive Phosphorus Dendrimers as a Universal Protein Delivery System for Enhanced Anti-inflammation Therapy.

Sun, Huxiao / Zhan, Mengsi / Karpus, Andrii / Zou, Yu / Li, Jin / Mignani, Serge / Majoral, Jean-Pierre / Shi, Xiangyang / Shen, Mingwu

ACS nano

2024 Volume 18, Issue 3, Page(s) 2195–2209

Abstract: Nanocarrier-based cytoplasmic protein delivery offers opportunities to develop protein therapeutics; however, many delivery systems are positively charged, causing severe toxic effects. For enhanced therapeutics, it is also of great importance to design ... ...

Abstract	Nanocarrier-based cytoplasmic protein delivery offers opportunities to develop protein therapeutics; however, many delivery systems are positively charged, causing severe toxic effects. For enhanced therapeutics, it is also of great importance to design nanocarriers with intrinsic bioactivity that can be integrated with protein drugs due to the limited bioactivity of proteins alone for disease treatment. We report here a protein delivery system based on anionic phosphite-terminated phosphorus dendrimers with intrinsic anti-inflammatory activity. A phosphorus dendrimer termed AK-137 with optimized anti-inflammatory activity was selected to complex proteins through various physical interactions. Model proteins such as bovine serum albumin, ribonuclease A, ovalbumin, and fibronectin (FN) can be transfected into cells to exert their respective functions, including cancer cell apoptosis, dendritic cell maturation, or macrophage immunomodulation. Particularly, the constructed AK-137@FN nanocomplexes display powerful therapeutic effects in acute lung injury and acute gout arthritis models by integrating the anti-inflammatory activity of both the carrier and protein. The developed anionic phosphite-terminated phosphorus dendrimers may be employed as a universal carrier for protein delivery and particularly utilized to deliver proteins and fight different inflammatory diseases with enhanced therapeutic efficacy.
MeSH term(s)	Dendrimers/pharmacology ; Phosphorus ; Phosphites ; Proteins ; Anti-Inflammatory Agents/pharmacology ; Anti-Inflammatory Agents/therapeutic use
Chemical Substances	Dendrimers ; Phosphorus (27YLU75U4W) ; Phosphites ; Proteins ; Anti-Inflammatory Agents
Language	English
Publishing date	2024-01-09
Publishing country	United States
Document type	Journal Article
ISSN	1936-086X
ISSN (online)	1936-086X
DOI	10.1021/acsnano.3c09589
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Brain Delivery of Biomimetic Phosphorus Dendrimer/Antibody Nanocomplexes for Enhanced Glioma Immunotherapy via Immune Modulation of T Cells and Natural Killer Cells.

Peng, Yamin / Zhan, Mengsi / Karpus, Andrii / Zou, Yu / Mignani, Serge / Majoral, Jean-Pierre / Shi, Xiangyang / Shen, Mingwu

ACS nano

2024 Volume 18, Issue 14, Page(s) 10142–10155

Abstract: Fully mobilizing the activities of multiple immune cells is crucial to achieve the desired tumor immunotherapeutic efficacy yet still remains challenging. Herein, we report a nanomedicine formulation based on phosphorus dendrimer (termed AK128)/ ... ...

Abstract	Fully mobilizing the activities of multiple immune cells is crucial to achieve the desired tumor immunotherapeutic efficacy yet still remains challenging. Herein, we report a nanomedicine formulation based on phosphorus dendrimer (termed AK128)/programmed cell death protein 1 antibody (aPD1) nanocomplexes (NCs) that are camouflaged with M1-type macrophage cell membranes (M1m) for enhanced immunotherapy of orthotopic glioma. The constructed AK128-aPD1@M1m NCs with a mean particle size of 160.3 nm possess good stability and cytocompatibility. By virtue of the decorated M1m having α
MeSH term(s)	Humans ; Dendrimers ; Phosphorus ; Leukocytes, Mononuclear/metabolism ; Leukocytes, Mononuclear/pathology ; Biomimetics ; Glioma/therapy ; Glioma/pathology ; Immunotherapy ; Killer Cells, Natural ; Antibodies/metabolism ; T-Lymphocytes, Cytotoxic ; Blood-Brain Barrier/metabolism ; Tumor Microenvironment
Chemical Substances	Dendrimers ; Phosphorus (27YLU75U4W) ; Antibodies
Language	English
Publishing date	2024-03-25
Publishing country	United States
Document type	Journal Article
ISSN	1936-086X
ISSN (online)	1936-086X
DOI	10.1021/acsnano.3c13088
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article: Crown Macromolecular Derivatives: Stepwise Design of New Types of Polyfunctionalized Phosphorus Dendrimers

Karpus, Andrii / Mignani, Serge / Zablocka, Maria / Majoral, Jean Pierre

Journal of organic chemistry. 2022 Feb. 10, v. 87, no. 5

2022

Abstract: Phosphorus dendrimers are used for many applications in different domains including nanomedicine as cargo of drugs or as species active per se but also in a variety of other fields ranging from nanoscience to catalysis. Their properties depend on the ... ...

Abstract	Phosphorus dendrimers are used for many applications in different domains including nanomedicine as cargo of drugs or as species active per se but also in a variety of other fields ranging from nanoscience to catalysis. Their properties depend on the nature of their internal structure and mainly of the diversity and versatility of the functional groups located on their outer shell. Therefore, there is a need to diversify their structure in order to use them for new applications and to propose alternative synthetic pathways to be built easily, at each step and in high yield a family of original stable phosphorus dendrimers of different generations. Such a goal is illustrated in this report with the original synthesis of 14 new phosphorus dendrimers of generation 0 to 2 and the possibility to modify at will their internal structure and the nature of their functional end groups.
Keywords	catalytic activity ; dendrimers ; nanomedicine ; organic chemistry ; phosphorus
Language	English
Dates of publication	2022-0210
Size	p. 3433-3441.
Publishing place	American Chemical Society
Document type	Article
ZDB-ID	123490-0
ISSN	1520-6904 ; 0022-3263
ISSN (online)	1520-6904
ISSN	0022-3263
DOI	10.1021/acs.joc.1c03009
Database	NAL-Catalogue (AGRICOLA)

In stock of ZB MED Bonn / Germany

Z 4' 49/42: Show issues
Z 7.1: Show issues

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Details ▾
- See ZB MED holdings
- Order with fees

Article: Well-Defined Pᴵᴵᴵ-Terminated Polymers from Phosphorylated Carbodithioate RAFT Agents

Karpus, Andrii / Harrisson, Simon / Poli, Rinaldo / Mazières, Stéphane / Manoury, Eric / Destarac, Mathias

Macromolecules. 2021 Mar. 08, v. 54, no. 6

2021

Abstract: Five S-alkyl di-tert-butylphosphorylated carbodithioates, Z–C(S)SR, were studied as chain transfer agents (CTAs) in the RAFT polymerization of vinyl monomers. These phosphorus-containing CTAs involve new Pᴵᴵᴵ and Pⱽ moieties in the Z group (phosphine- ... ...

Abstract	Five S-alkyl di-tert-butylphosphorylated carbodithioates, Z–C(S)SR, were studied as chain transfer agents (CTAs) in the RAFT polymerization of vinyl monomers. These phosphorus-containing CTAs involve new Pᴵᴵᴵ and Pⱽ moieties in the Z group (phosphine-borane or free phosphine). Two of them, with an S-bonded 1-methoxycarbonylethyl group as leaving group, have not previously been described. The CTAs with a Pⱽ Z group provide good control over the polymerization of styrene (St) and n-butyl acrylate (nBA). Molar masses are close to theoretical values, and dispersities are consistently low during polymerization. The monitoring of polymerization by ³¹P NMR spectroscopy supports the controlled character and the integrity of the polymer chain ends. Conversely, they inhibit the polymerization of the less-activated monomer vinyl acetate (VAc). The reactivity of the CTAs with a Pᴵᴵᴵ Z group mainly depends on the reaction medium, and their performance for St, nBA, and VAc was surprising and unexpected. Theoretical calculations were carried out to rationalize their behavior. Finally, an innovative strategy was developed to obtain well-controlled polymers with free phosphine ω-chain ends.
Keywords	nuclear magnetic resonance spectroscopy ; phosphine ; polymerization ; polymers ; styrene ; vinyl acetate
Language	English
Dates of publication	2021-0308
Size	p. 2627-2636.
Publishing place	American Chemical Society
Document type	Article
Note	NAL-AP-2-clean
ZDB-ID	1491942-4
ISSN	1520-5835 ; 0024-9297
ISSN (online)	1520-5835
ISSN	0024-9297
DOI	10.1021/acs.macromol.0c02805
Database	NAL-Catalogue (AGRICOLA)

Order via subito

Article: Clinical diagonal translation of nanoparticles: Case studies in dendrimer nanomedicine

Mignani, Serge / Shi, Xiangyang / Guidolin, Keegan / Zheng, Gang / Karpus, Andrii / Majoral, Jean-Pierre

Journal of controlled release. 2021 Sept. 10, v. 337

2021

Abstract: Among the numerous nanomedicine formulations, dendrimers have emerged as original, efficient, carefully assembled, hyperbranched, polymeric nanoparticles based on synthetic monomers. Dendrimers are used either as nanocarriers of drugs or as drugs ... ...

Abstract	Among the numerous nanomedicine formulations, dendrimers have emerged as original, efficient, carefully assembled, hyperbranched, polymeric nanoparticles based on synthetic monomers. Dendrimers are used either as nanocarriers of drugs or as drugs themselves. When used as drug carriers, dendrimers are considered ‘best-in-class agents’, modifying and enhancing the pharmacokinetic and pharmacodynamic properties of the active entities encapsulated or conjugated with the dendrimers. When used as drugs themselves, dendrimers represent a novel category of “first-in-class” drugs. The purpose of this original review is to analyse the different strategies involved in the development, application, and impact of dendrimers as drugs. We examine a selection of nanoparticles that use multifunctional elements and demonstrate clinical multifunctionality, and we extend these principles to applications in dendrimer nanomedicine design. Finally, for practical consideration, the concepts of vertical and diagonal translation are introduced as potential strategies to facilitate dendrimer development.
Keywords	dendrimers ; drugs ; nanocarriers ; nanomedicine ; pharmacodynamics ; pharmacokinetics
Language	English
Dates of publication	2021-0910
Size	p. 356-370.
Publishing place	Elsevier B.V.
Document type	Article
ZDB-ID	632533-6
ISSN	1873-4995 ; 0168-3659
ISSN (online)	1873-4995
ISSN	0168-3659
DOI	10.1016/j.jconrel.2021.07.036
Database	NAL-Catalogue (AGRICOLA)

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 2055: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Unsymmetrical Low-Generation Cationic Phosphorus Dendrimers as a Nonviral Vector to Deliver MicroRNA for Breast Cancer Therapy.

Zou, Yu / Shen, Siyan / Karpus, Andrii / Sun, Huxiao / Laurent, Regis / Caminade, Anne-Marie / Shen, Mingwu / Mignani, Serge / Shi, Xiangyang / Majoral, Jean-Pierre

Biomacromolecules

2024 Volume 25, Issue 2, Page(s) 1171–1179

Abstract: The development of nonviral dendritic polymers with a simple molecular backbone and great gene delivery efficiency to effectively tackle cancer remains a great challenge. Phosphorus dendrimers or dendrons are promising vectors due to their structural ... ...

Abstract	The development of nonviral dendritic polymers with a simple molecular backbone and great gene delivery efficiency to effectively tackle cancer remains a great challenge. Phosphorus dendrimers or dendrons are promising vectors due to their structural uniformity, rigid molecular backbones, and tunable surface functionalities. Here, we report the development of a new low-generation unsymmetrical cationic phosphorus dendrimer bearing 5 pyrrolidinium groups and one amino group as a nonviral gene delivery vector. The created
MeSH term(s)	Animals ; Mice ; Dendrimers/chemistry ; Genetic Vectors ; MicroRNAs/genetics ; Gene Transfer Techniques ; Cations ; Phosphorus ; Neoplasms
Chemical Substances	Dendrimers ; MicroRNAs ; Cations ; Phosphorus (27YLU75U4W)
Language	English
Publishing date	2024-01-05
Publishing country	United States
Document type	Journal Article
ISSN	1526-4602
ISSN (online)	1526-4602
DOI	10.1021/acs.biomac.3c01169
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Non-invasive intranasal administration route directly to the brain using dendrimer nanoplatforms: An opportunity to develop new CNS drugs.

Mignani, Serge / Shi, Xiangyang / Karpus, Andrii / Majoral, Jean-Pierre

European journal of medicinal chemistry

2020 Volume 209, Page(s) 112905

Abstract: There are several routes of administration to the brain, including intraparenchymal, intraventricular, and subarachnoid injections. The blood-brain barrier (BBB) impedes the permeation and access of most drugs to the central nervous system (CNS), and ... ...

Abstract	There are several routes of administration to the brain, including intraparenchymal, intraventricular, and subarachnoid injections. The blood-brain barrier (BBB) impedes the permeation and access of most drugs to the central nervous system (CNS), and consequently, many neurological diseases remain undertreated. For past decades, to circumvent this effect, several nanocarriers have been developed to deliver drugs to the brain. Importantly, intranasal (IN) administration can allow direct delivery of drugs into the brain through the anatomical connection between the nasal cavity and brain without crossing the BBB. In this regard, dendrimers may possess great potential to deliver drugs to the brain by IN administration, bypassing the BBB and reducing systemic exposure and side effects, to treat diseases of the CNS. In this original concise review, we highlighted the few examples advocated regarding the use of dendrimers to deliver CNS drugs directly via IN. This review highlighed the few examples of the association of dendrimer encapsulating drugs (e.g., small compounds: haloperidol and paeonol; macromolecular compounds: dextran, insulin and calcitonin; and siRNA) using IN administration. Good efficiencies were observed. In addition, we will present the in vivo effects of PAMAM dendrimers after IN administration, globally, showing no general toxicity.
MeSH term(s)	Acetophenones/administration & dosage ; Acetophenones/chemistry ; Administration, Intranasal ; Animals ; Biological Transport ; Blood-Brain Barrier/metabolism ; Calcitonin/administration & dosage ; Calcitonin/chemistry ; Central Nervous System Agents/pharmacology ; Dendrimers/chemistry ; Dextrans/administration & dosage ; Dextrans/chemistry ; Drug Liberation ; Haloperidol/administration & dosage ; Haloperidol/chemistry ; Humans ; Insulin/administration & dosage ; Insulin/chemistry ; Nanocapsules/chemistry ; RNA, Small Interfering/administration & dosage ; RNA, Small Interfering/chemistry ; Technology, Pharmaceutical
Chemical Substances	Acetophenones ; Central Nervous System Agents ; Dendrimers ; Dextrans ; Insulin ; Nanocapsules ; PAMAM Starburst ; RNA, Small Interfering ; paeonol (3R834EPI82) ; Calcitonin (9007-12-9) ; Haloperidol (J6292F8L3D)
Keywords	covid19
Language	English
Publishing date	2020-10-11
Publishing country	France
Document type	Journal Article ; Review
ZDB-ID	188597-2
ISSN	1768-3254 ; 0009-4374 ; 0223-5234
ISSN (online)	1768-3254
ISSN	0009-4374 ; 0223-5234
DOI	10.1016/j.ejmech.2020.112905
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.B 784: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article: Functionalized Dendrimer Platforms as a New Forefront Arsenal Targeting SARS-CoV-2: An Opportunity.

Mignani, Serge / Shi, Xiangyang / Karpus, Andrii / Lentini, Giovanni / Majoral, Jean-Pierre

Pharmaceutics

2021 Volume 13, Issue 9

Abstract: The novel human coronavirus SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) has caused a pandemic. There are currently several marketed vaccines and many in clinical trials targeting SARS-CoV-2. Another strategy is to repurpose approved ... ...

Abstract	The novel human coronavirus SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) has caused a pandemic. There are currently several marketed vaccines and many in clinical trials targeting SARS-CoV-2. Another strategy is to repurpose approved drugs to decrease the burden of the COVID-19 (official name for the coronavirus disease) pandemic. as the FDA (U.S. Food and Drug Administration) approved antiviral drugs and anti-inflammatory drugs to arrest the cytokine storm, inducing the production of pro-inflammatory cytokines. Another view to solve these unprecedented challenges is to analyze the diverse nanotechnological approaches which are able to improve the COVID-19 pandemic. In this original minireview, as promising candidates we analyze the opportunity to develop biocompatible dendrimers as drugs themselves or as nanocarriers against COVID-19 disease. From the standpoint of COVID-19, we suggest developing dendrimers as shields against COVID-19 infection based on their capacity to be incorporated in several environments outside the patients and as important means to stop transmission of SARS-CoV-2.
Language	English
Publishing date	2021-09-18
Publishing country	Switzerland
Document type	Journal Article ; Review
ZDB-ID	2527217-2
ISSN	1999-4923
ISSN	1999-4923
DOI	10.3390/pharmaceutics13091513
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: First-in-class and best-in-class dendrimer nanoplatforms from concept to clinic: Lessons learned moving forward.

Mignani, Serge / Shi, Xangyang / Rodrigues, João / Tomas, Helena / Karpus, Andrii / Majoral, Jean-Pierre

European journal of medicinal chemistry

2021 Volume 219, Page(s) 113456

Abstract: Research to develop active dendrimers by themselves or as nanocarriers represents a promising approach to discover new biologically active entities that can be used to tackle unmet medical needs including difficult diseases. These developments are ... ...

Abstract	Research to develop active dendrimers by themselves or as nanocarriers represents a promising approach to discover new biologically active entities that can be used to tackle unmet medical needs including difficult diseases. These developments are possible due to the exceptional physicochemical properties of dendrimers, including their biocompatibility, as well as their therapeutic activity as nanocarriers and drugs themselves. Despite a large number of academic studies, very few dendrimers have crossed the 'valley of death' between. Only a few number of pharmaceutical companies have succeeded in this way. In fact, only Starpharma (Australia) and Orpheris, Inc. (USA), an Ashvattha Therapeutics subsidiary, can fill all the clinic requirements to have in the market dendrimers based drugs/nancocarriers. After evaluating the main physicochemical properties related to the respective biological activity of dendrimers classified as first-in-class or best-in-class in nanomedicine, this original review analyzes the advantages and disavantages of these two strategies as well the concerns to step in clinical phases. Various solutions are proposed to advance the use of dendrimers in human health.
MeSH term(s)	Biocompatible Materials/chemistry ; Biocompatible Materials/metabolism ; Dendrimers/chemistry ; Dendrimers/metabolism ; Drug Carriers/chemistry ; Drug Liberation ; Half-Life ; Humans ; Nanomedicine ; Pharmaceutical Preparations/chemistry ; Pharmaceutical Preparations/metabolism
Chemical Substances	Biocompatible Materials ; Dendrimers ; Drug Carriers ; Pharmaceutical Preparations
Language	English
Publishing date	2021-04-17
Publishing country	France
Document type	Journal Article ; Review
ZDB-ID	188597-2
ISSN	1768-3254 ; 0009-4374 ; 0223-5234
ISSN (online)	1768-3254
ISSN	0009-4374 ; 0223-5234
DOI	10.1016/j.ejmech.2021.113456
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.B 784: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

To top

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Bonn / Germany

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito